scholarly article | Q13442814 |
P50 | author | Steven Rosenberg | Q2347448 |
P2093 | author name string | Kawakami Y | |
Li YF | |||
Robbins PF | |||
El-Gamil M | |||
Fitzgerald EB | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 303-308 | |
P577 | publication date | 1997-07-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes | |
P478 | volume | 159 |
Q22010943 | A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription |
Q37476322 | A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats. |
Q30865419 | A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. |
Q36121851 | Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation |
Q34347168 | Alternative translational reading frames as a novel source of epitopes for an expanded CD8 T-cell repertoire: use of a retroviral system to assess the translational requirements for CTL recognition and lysis |
Q91666603 | Alternative tumour-specific antigens |
Q42058413 | An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes |
Q34192290 | An antigenic peptide produced by reverse splicing and double asparagine deamidation |
Q37390912 | B16 as a mouse model for human melanoma |
Q28146219 | Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide |
Q27022422 | Database of T cell-defined human tumor antigens: the 2013 update |
Q91782530 | Determinants for Neoantigen Identification |
Q87335130 | Developing effective tumor vaccines: basis, challenges and perspectives |
Q35946196 | Developing recombinant and synthetic vaccines for the treatment of melanoma. |
Q34647354 | Development of effective immunotherapy for the treatment of patients with cancer |
Q37139813 | Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling |
Q47797670 | Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy |
Q28361963 | Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients |
Q28138549 | Expression of tumor-rejection antigens in gynecologic cancers |
Q41687574 | Human tumor antigens recognized by T-cells |
Q38731152 | I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells |
Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
Q42835548 | Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions |
Q37851050 | Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes |
Q36696205 | Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma |
Q34768462 | Non-conventional sources of peptides presented by MHC class I. |
Q34401747 | Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing |
Q34173622 | Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402 |
Q24646800 | Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage |
Q34374454 | Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway |
Q36438078 | Tumor antigens discovery: perspectives for cancer therapy |
Q26796314 | Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges |
Q40264818 | Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands. |
Search more.